OR WAIT null SECS
January 03, 2019
AbbVie and immunotherapy company Tizona Therapeutics will join forces to develop and commercialize CD39-targeted therapeutics to treat cancer.
December 26, 2018
The companies will join forces to develop and commercialize an oncology drug to treat hematological cancers.
December 21, 2018
The agency has approved Stemline Therapeutics’ Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm for both adults and pediatric patients.
December 18, 2018
Agilent and other partners are funding development of Tapestri, a single-cell sequencing platform designed to help predict cancer relapse in individual patients and show the efficacy of gene-editing experiments.
December 10, 2018
FDA has approved Truxima (rituximab-abbs), a biosimilar to Roche’s anti-cancer biologic, Rituxan (rituximab).
The companies aim to advance research into inflammatory bowel disease.
November 30, 2018
The acquisition will give Genentech full rights to Jecure’s preclinical portfolio of NLRP3 inhibitors.
November 29, 2018
Charles River Laboratories has announced a data expansion in its compendium of tumor models for oncology drug R&D.
November 27, 2018
The agency has approved two new chemical entities, Daurismo (glasdegib) from Pfizer, and Vitrakvi (larotrectinib) from Loxo Oncology, for treating cancers.
November 16, 2018
The companies will develop AMG 714, a novel anti-IL-15 monoclonal antibody, for the treatment of gluten-free diet non-responsive celiac disease in a collaboration worth $170 million.